Veracyte (VCYT) Competitors

Veracyte logo
$24.01 -0.32 (-1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$23.90 -0.11 (-0.46%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VCYT vs. GMED, WST, ASND, BBIO, and HALO

Should you buy Veracyte stock or one of its competitors? Veracyte's main competitors and comparable companies include Globus Medical (GMED), West Pharmaceutical Services (WST), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Veracyte compare to Globus Medical?

Veracyte (NASDAQ:VCYT) and Globus Medical (NYSE:GMED) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Veracyte currently has a consensus target price of $44.50, indicating a potential upside of 82.90%. Globus Medical has a consensus target price of $96.08, indicating a potential upside of 33.42%. Given Veracyte's higher probable upside, equities analysts plainly believe Veracyte is more favorable than Globus Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

Veracyte has a net margin of 21.80% compared to Globus Medical's net margin of 17.76%. Globus Medical's return on equity of 14.43% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte21.80% 8.99% 8.34%
Globus Medical 17.76%14.43%12.52%

Veracyte has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

In the previous week, Veracyte had 5 more articles in the media than Globus Medical. MarketBeat recorded 21 mentions for Veracyte and 16 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.14 beat Veracyte's score of -0.01 indicating that Globus Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
2 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral
Globus Medical
5 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.2% of Globus Medical shares are held by institutional investors. 1.6% of Veracyte shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Globus Medical has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M3.80$66.35M$1.5515.70
Globus Medical$2.94B3.25$537.87M$4.0717.69

Summary

Globus Medical beats Veracyte on 12 of the 17 factors compared between the two stocks.

How does Veracyte compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

West Pharmaceutical Services presently has a consensus price target of $424.67, suggesting a potential upside of 2.00%. Veracyte has a consensus price target of $44.50, suggesting a potential upside of 82.90%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42

West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Veracyte has a net margin of 21.80% compared to West Pharmaceutical Services' net margin of 18.81%. West Pharmaceutical Services' return on equity of 21.78% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services18.81% 21.78% 15.99%
Veracyte 21.80%8.99%8.34%

In the previous week, Veracyte had 11 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 21 mentions for Veracyte and 10 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 1.12 beat Veracyte's score of -0.01 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veracyte
2 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral

West Pharmaceutical Services has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B9.43$493.70M$8.9146.73
Veracyte$517.15M3.80$66.35M$1.5515.70

Summary

West Pharmaceutical Services beats Veracyte on 11 of the 16 factors compared between the two stocks.

How does Veracyte compare to Ascendis Pharma A/S?

Veracyte (NASDAQ:VCYT) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Veracyte currently has a consensus price target of $44.50, suggesting a potential upside of 82.90%. Ascendis Pharma A/S has a consensus price target of $313.52, suggesting a potential upside of 13.85%. Given Veracyte's higher possible upside, research analysts clearly believe Veracyte is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42
Ascendis Pharma A/S
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.90

Veracyte has higher earnings, but lower revenue than Ascendis Pharma A/S. Veracyte is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M3.80$66.35M$1.5515.70
Ascendis Pharma A/S$814.57M21.09-$258M$15.3018.00

Ascendis Pharma A/S has a net margin of 73.26% compared to Veracyte's net margin of 21.80%. Ascendis Pharma A/S's return on equity of 32.47% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte21.80% 8.99% 8.34%
Ascendis Pharma A/S 73.26%32.47%13.26%

Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Veracyte. MarketBeat recorded 28 mentions for Ascendis Pharma A/S and 21 mentions for Veracyte. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Veracyte's score of -0.01 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
2 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ascendis Pharma A/S
7 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Ascendis Pharma A/S beats Veracyte on 11 of the 14 factors compared between the two stocks.

How does Veracyte compare to BridgeBio Pharma?

Veracyte (NASDAQ:VCYT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Veracyte has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M3.80$66.35M$1.5515.70
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A

Veracyte has a net margin of 21.80% compared to BridgeBio Pharma's net margin of -59.84%. Veracyte's return on equity of 8.99% beat BridgeBio Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte21.80% 8.99% 8.34%
BridgeBio Pharma -59.84%N/A -39.81%

In the previous week, Veracyte had 9 more articles in the media than BridgeBio Pharma. MarketBeat recorded 21 mentions for Veracyte and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Veracyte's score of -0.01 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
2 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.8% of BridgeBio Pharma shares are held by institutional investors. 1.6% of Veracyte shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Veracyte has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Veracyte presently has a consensus target price of $44.50, indicating a potential upside of 82.90%. BridgeBio Pharma has a consensus target price of $104.42, indicating a potential upside of 33.36%. Given Veracyte's higher probable upside, equities research analysts plainly believe Veracyte is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Veracyte beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Veracyte compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Halozyme Therapeutics has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51
Veracyte$517.15M3.80$66.35M$1.5515.70

Halozyme Therapeutics presently has a consensus price target of $108.18, suggesting a potential upside of 7.89%. Veracyte has a consensus price target of $44.50, suggesting a potential upside of 82.90%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42

Halozyme Therapeutics has a net margin of 26.93% compared to Veracyte's net margin of 21.80%. Halozyme Therapeutics' return on equity of 751.81% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics26.93% 751.81% 23.84%
Veracyte 21.80%8.99%8.34%

In the previous week, Veracyte had 9 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 21 mentions for Veracyte and 12 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.13 beat Veracyte's score of -0.01 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veracyte
2 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral

Halozyme Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Summary

Halozyme Therapeutics beats Veracyte on 13 of the 16 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCYT vs. The Competition

MetricVeracyteBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.99B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio16.2026.5532.9127.37
Price / Sales3.7516.058.595.73
Price / Cash16.5326.3721.9322.50
Price / Book1.354.074.403.70
Net Income$66.35M-$22.86M$3.52B$392.17M
7 Day Performance-7.37%-7.26%-5.34%-4.53%
1 Month Performance-44.32%-4.96%-3.61%-5.86%
1 Year Performance-38.98%-2.87%0.01%-7.78%

Veracyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
3.2682 of 5 stars
$24.01
-1.3%
$44.50
+85.3%
-38.2%$1.99B$517.15M16.20755
GMED
Globus Medical
3.8258 of 5 stars
$76.60
+7.8%
$96.08
+25.4%
-14.6%$11.69B$2.94B17.706,000
WST
West Pharmaceutical Services
3.9353 of 5 stars
$413.30
+3.4%
$424.67
+2.7%
+59.5%$28.48B$3.07B46.3910,800
ASND
Ascendis Pharma A/S
4.2447 of 5 stars
$259.85
+1.2%
$305.95
+17.7%
+34.7%$16.09B$814.57M20.161,189
BBIO
BridgeBio Pharma
3.5932 of 5 stars
$77.93
+4.9%
$104.26
+33.8%
+17.9%$15.17B$502.08MN/A839

Related Companies and Tools


This page (NASDAQ:VCYT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners